Shares of AbbVie Inc. ABBV slid 3.14% to $174.20 Thursday, on what proved to be an all-around dismal trading session for the ...

We recently published a list of the 10 High Growth Forever Dividend Stocks to Invest In. In this article, we are going to ...

We recently published a list of the 10 Best Dividend Monarchs to Invest in Now. In this article, we are going to take a look ...

Today's Research Daily features new research reports on 16 major stocks, including AbbVie Inc. (ABBV), The TJX Companies, Inc ...

In this article, we are going to take a look at where AbbVie Inc. (NYSE:ABBV) stands against other best stocks for 15 years. Russell Investments believes that 3 features are defining the market ...

ClearBridge Investments, an investment management company, released its “ClearBridge Growth Strategy” first quarter 2025 ...

A recent selloff of Neurocrine Biosciences stock feels unwarranted and may have created a contrarian buy opportunity. Learn ...

The 340B program requires drugmakers who want to participate in Medicaid and Medicare to discount their prices for hospitals, clinics and other providers that serve low-income patients. Those “covered ...

Shares of AbbVie Inc. (NYSE:ABBV – Get Free Report) dropped 0.2% during trading on Thursday after an insider sold shares in the company. The stock traded as low as $204.55 and last traded at $204.69.

AbbVie is grappling with diminishing Humira sales and is also trading at an above-average P/E. See why I rate ABBV stock as a hold.

Learn more about whether Neurocrine Biosciences, Inc. or TG Therapeutics, Inc. is a better investment based on AAII's A+ ...